News

Dow Inc. Revises Earnings Forecast Following Production Issues

Dow Inc. Revises Earnings Forecast Following Production Issues

Dow Inc. Faces Production Hurdles and Adjusts Earnings Forecast

Dow Inc. (NYSE: DOW) is making news as its stock is dipping, prompted by a revised outlook for its third-quarter earnings. This change was driven by significant production hurdles, especially at a Texas ethylene cracker that experienced an unexpected shutdown back in late July.

Updated Earnings Outlook

In its revised forecast, Dow has adjusted its expected revenue down to about $10.6 billion, a drop from the earlier estimate of $11.1 billion. This new projection falls short of the consensus expectation of $11.0 billion. Additionally, the company expects its operating EBITDA to hover around $1.3 billion.

Reasons for the Adjusted Projections

This downward adjustment largely stems from unexpected outages and rising input costs, along with margin pressures notably in the European market. However, there’s a glimmer of hope as the company anticipates that price improvements and more favorable feedstock costs in North America, particularly in the Packaging & Specialty Plastics segment, will help mitigate the effects of these challenges.

Insights from the CEO on Market Conditions

Jim Fitterling, Dow's chair and CEO, remarked, “Looking ahead to the fourth quarter, we foresee typical seasonal demand. Nevertheless, we also expect benefits from reduced turnaround costs and increased operating rates as we ramp up production at our Texas cracker, along with fewer weather disruptions along the U.S. Gulf Coast.” This indicates that despite ongoing challenges, Dow is proactively addressing the issues it faces.

Recent Financial Results

In its second-quarter report, Dow revealed a year-over-year (Y/Y) sales decline of 4%, bringing sales down to $10.9 billion, which was below the estimated figure of $11.01 billion. Adjusted earnings per share were reported at $0.68, also falling short of the consensus estimate of $0.72. Operating EBIT for the quarter decreased, standing at $819 million.

Investment Options

For those looking to invest in Dow Inc., two options worth considering are the Invesco Dow Jones Industrial Average Dividend ETF (NYSE: DJD) and the FT Vest DJIA Dogs 10 Target Income ETF (BATS: DOGG), which may provide good exposure to the company.

Current Stock Performance

As of the latest updates, DOW shares have seen a decrease of 1.20%, trading at around $50.12. This decline reflects the broader market’s response to the company’s revised earnings outlook and ongoing operational challenges.

Frequently Asked Questions

What led to Dow Inc. revising its earnings forecast?

Dow Inc. revised its earnings forecast primarily due to considerable production issues, including an unplanned shutdown at its Texas ethylene cracker, alongside rising input costs.

What is the adjusted revenue expectation for Dow Inc.?

The adjusted revenue outlook for Dow Inc. is approximately $10.6 billion, which is a reduction from prior estimates.

How did Dow perform in the second quarter?

During the second quarter, Dow reported a sales decline of 4% Y/Y, amounting to $10.9 billion and falling short of expectations.

What investment opportunities exist for Dow Inc.?

Potential investors might explore ETFs like the Invesco Dow Jones Industrial Average Dividend ETF (DJD) and the FT Vest DJIA Dogs 10 Target Income ETF (DOGG) for exposure to Dow Inc.

What is the current stock status of Dow Inc.?

DOW shares are currently down by 1.20%, trading at about $50.12.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation Alerts for Spyre Therapeutics Investors Amid Concerns

Updated Category News Views 143

Investigation of Claims for Spyre Therapeutics Investors Pomerantz LLP is currently investigating claims on behalf of investors of Spyre Therapeutics, Inc. (NASDAQ: SYRE). The firm seeks to understand whether Spyre and its executives have potentially engaged in any unlawful business practices, specifically concerning securities fraud. Understanding the Securities Concerns...

Continue Reading
Natixis CIB's Pioneering Project Financing for Infrastructure

Updated Category News Views 126

Natixis CIB's Role in Groundbreaking Project Financing Natixis Corporate & Investment Banking (Natixis CIB) has taken a significant step in enhancing infrastructure development by serving as Joint Bookrunner and Joint Lead Arranger for a remarkable $281 million project financing. This financing initiative will support Ruta del Este, a concessionaire formed by ISA Vías to...

Continue Reading
Finch Therapeutics Moves to Delist from Nasdaq Amid Challenges

Updated Category News Views 177

Finch Therapeutics Plans Delisting from Nasdaq Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has recently announced its decision to delist from The Nasdaq Stock Market, LLC. This move is part of a broader strategy aimed at navigating current market challenges and optimizing operational efficiency. The company is a leader in microbiome technology, boasting a strong...

Continue Reading
ModivCare: Exploring Recent Developments and Stockholder Rights

Updated Category News Views 269

Investigating the Latest Events Surrounding ModivCare Recent events surrounding ModivCare, Inc. have drawn considerable attention from the investor community and law firms alike. This scrutiny comes after a class action lawsuit from long-term shareholders, alleging the company's management may have misled investors about its ability to manage its financial health during a...

Continue Reading
Investors in Avantor, Inc. Urged to Act Before Key Deadline

Updated Category News Views 157

A Call to Action for Avantor, Inc. Investors Investors in Avantor, Inc. should take heed of an essential notification regarding a securities class action. As a market participant interested in Avantor, Inc. (NYSE: AVTR), your involvement could be crucial. This class action centers around stock purchases made during a specific timeframe that is intended to hold the company...

Continue Reading